Benzinga · Mar 27, 2026
CD
NASDAQ · CDTTW
CDT Equity Inc. Warrant
Healthcare · Biotechnology
$0.01
Up+$0.00 (+1.02%)
Updated Sep 12, 2026, 12:34 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 17.92K
- P/E ratio
- -3.53
- Dividend yield
- 0.00%
- 52-week range
- $0.01 – $0.02
- Volume
- 11.29K
- Avg. volume
- 55.16K
Price performance
CDTTW price history
1M range · 15 trading sessions · Daily adjusted prices
CDTTW closed at $0.01 after 15 trading sessions, down 8.33% for the selected period.
- Last close
- $0.01
- Period change
- -8.33%
- Period low
- $0.01
- Period high
- $0.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0098 | $0.0099 | $0.0084 | $0.0099 | 11.29K |
| Sep 10, 2026 | $0.0099 | $0.0099 | $0.0098 | $0.0098 | 200 |
| Sep 9, 2026 | $0.0099 | $0.0099 | $0.0098 | $0.0098 | 210 |
| Sep 8, 2026 | $0.0099 | $0.0099 | $0.0098 | $0.0099 | 2.52K |
| Sep 3, 2026 | $0.0078 | $0.0107 | $0.0078 | $0.0106 | 15.11K |
| Sep 2, 2026 | $0.0109 | $0.0109 | $0.0108 | $0.0108 | 200 |
| Aug 31, 2026 | $0.0109 | $0.0109 | $0.0108 | $0.0108 | 200 |
| Aug 28, 2026 | $0.0109 | $0.0109 | $0.0108 | $0.0108 | 200 |
| Aug 27, 2026 | $0.0109 | $0.0109 | $0.0093 | $0.0094 | 1.16K |
| Aug 25, 2026 | $0.0107 | $0.0116 | $0.01 | $0.0116 | 10.26K |
| Aug 21, 2026 | $0.0107 | $0.0107 | $0.0087 | $0.0099 | 500 |
| Aug 20, 2026 | $0.0088 | $0.0114 | $0.0088 | $0.0096 | 75.22K |
| Aug 19, 2026 | $0.0097 | $0.0115 | $0.0097 | $0.0115 | 10.18K |
| Aug 18, 2026 | $0.0115 | $0.0115 | $0.0115 | $0.0115 | 100 |
| Aug 14, 2026 | $0.0119 | $0.012 | $0.0063 | $0.0108 | 227.13K |
Latest CDTTW news
The latest Smart Investors Daily articles mentioning CDTTW.
Stock researchCompany · Overview
CDTTW research
Overview
Company profile and research snapshot.
Company profile
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Mar 26, 2026
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
